LENZ Therapeutics, Inc. Price & Performance (LENZ)

Caribou Biosciences is reducing its staff by nearly one-third and discontinuing its lupus pipeline after a strategic pivot failed to yield results. The layoffs, affecting 47 employees, reflect ongoing volatility in the biotech sector as companies refocus on core cancer assets amid shifting market dynamics.1

A recent feasibility review has confirmed that Graphite One’s plan to establish a complete graphite supply chain in the United States is viable. This development comes as domestic supply security grows in importance, especially for critical battery and technology sectors reliant on graphite materials.2

The global point of care diagnostics market is expected to grow at a 12.7% CAGR, reaching nearly $83 billion by 2028. This surge is attributed to advances in rapid testing technologies and increased demand for decentralized healthcare solutions across both developed and emerging markets.3